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In Brief Foster et al. show that activation of M 4 muscarinic receptors on spiny projection neurons causes a sustained inhibition of dopaminergic signaling. M 4 -mediated reductions in dopaminergic signaling and concurrent antipsychotic-like efficacy were demonstrated to occur via a novel cannabinoid-dependent mechanism.
INTRODUCTION
Currently available treatments for schizophrenia are often effective in ameliorating psychotic symptoms, but also induce metabolic, cognitive, and motor side effects, limiting their therapeutic utility. The seminal finding that the M 1 /M 4 -preferring muscarinic acetylcholine receptor (mAChR) agonist xanomeline demonstrated robust antipsychotic efficacy in schizophrenia patients (Shekhar et al., 2008 ) generated a major interest in developing selective M 1 and M 4 agonists and understanding the roles of these receptors in forebrain circuits (Foster et al., 2014a) . Unfortunately, all known mAChR agonists are non-selective and activate peripheral M 2 and M 3 receptors, leading to adverse effects (Bymaster et al., 2003) . By targeting allosteric sights on mAChRs, we and others have succeeded in identifying highly subtype-selective positive allosteric modulators (PAMs) of individual mAChR subtypes that avoid activation of peripheral mAChRs. Interestingly, highly selective M 4 PAMs have robust antipsychotic-like effects in multiple rodent models. While the mechanisms by which M 4 PAMs exert their behavioral effects are not entirely clear, these compounds reverse multiple in vivo effects of psychomotor stimulants that induce increases in extracellular dopamine (DA; Bubser et al., 2014; Byun et al., 2014; Chan et al., 2008; Leach et al., 2010) . These studies raise the possibility that M 4 PAMs may act by inhibiting DA release from midbrain DA neurons. However, the hypothesis that selective M 4 PAMs inhibit DA release has not been directly tested. Furthermore, while M 4 can act as a presynaptic heteroreceptor to inhibit glutamate release in the striatum (Pancani et al., 2014) , this receptor is not expressed in DA neurons and is not likely to inhibit DA release by direct actions on DA terminals. We now report that activation of M 4 induces a sustained inhibition of electrically or optically induced DA release in midbrain slices that is potentiated by M 4 PAMs and persists for more than 30 min after receptor activation. This sustained inhibition of DA release is independent of nicotinic receptor (nAChR) signaling, suggesting that it is not mediated by autoreceptors on cholinergic interneurons. Instead, use of genetically modified mice revealed that this sustained inhibition of striatal DA release is mediated by M 4 expressed on a subpopulation of striatal spiny projection neurons (SPNs) that express D 1 DA receptors (D 1 -SPNs). Surprisingly, both the sustained inhibition of DA release and antipsychoticlike behavioral effects induced by an M 4 PAM were found to require intact endocannabinoid (eCB)-mediated CB 2 cannabinoid receptor signaling. Taken together, these studies identify a novel signaling pathway through which activation of M 4 receptors on SPNs dampens dopaminergic signaling and highlights the importance of this pathway to the antipsychotic-like efficacy observed with M 4 PAMs.
RESULTS
mAChR Activation Induces a Sustained Inhibition of DA Release that Is Independent of nAChR Signaling We determined the ability of mAChR activation to modulate striatal DA release by bath applying the non-selective mAChR agonist oxotremorine-M (Oxo-M), while monitoring electrically evoked DA release via fast scan voltammetry ( Figure S1A , available online). Consistent with previous studies (Threlfell et al., 2010; Zhang et al., 2002) , addition of 10 mM Oxo-M caused a transient inhibition of DA release that returned to baseline within 10 min of removing Oxo-M from the bath ( Figure 1A ). However, at higher concentrations (30 mM), Oxo-M induced a sustained inhibition of DA release that persisted long after (>30 min) drug washout ( Figure 1B) .
Previous studies have demonstrated that electrical stimulation of cholinergic afferents in the striatum can increase tonic DA release by activation of b2-containing nicotinic ACh receptors (nAChRs) on DA neuron terminals (Champtiaux et al., 2003) . Furthermore, mAChR inhibition of DA release induced by electrical stimulation in striatal slices has been ascribed in large part to activation of mAChR autoreceptors on cholinergic terminals that inhibit ACh release and thereby inhibit nAChR-mediated increases in DA release (Threlfell et al., 2010) . To assess the effects of mAChR activation on nAChR-independent DA release, we pretreated the slices with the b2-selective nAChR antagonist dihydro-b-erythroidine hydrobromide (DHbE, 1 mM). Pretreatment with DHbE completely blocked DA release induced by optical stimulation of cholinergic interneurons ( Figure S1B ), while partially blocking electrically induced DA transients ( Figure S1C ). This suggests that this nAChR antagonist can completely inhibit nAChR-mediated increases in DA release as previously observed (Threlfell et al., 2012) . Pretreatment with DHbE significantly reduced the Oxo-M induced inhibition of electrically evoked DA release at early time points ( Figures 1C and 1E ). However, the Oxo-M-induced sustained inhibition was not significantly altered by DHbE pretreatment ( Figures 1C and 1F ), suggesting that this sustained inhibition of DA release is not mediated by inhibition of nAChR effects. To remove effects of electrical stimulation on cholinergic terminals and selectively activate DA terminals, we utilized mice that selectively express ChR2 in DA transporter (DAT)-expressing neurons (DAT-Cre x ChR2 mice). Optical stimulation in slices from DAT-Cre x ChR2 mice induced robust DA transients ( Figure S1D ). In these mice, application of 30 mM Oxo-M had a blunted effect at early time points ( Figures 1D and 1E ), whereas the sustained inhibition at later time points was unchanged ( Figures 1D and 1F) . Importantly, inclusion of DHbE had no effect on optically evoked DA transients or Oxo-M mediated regulation of optically evoked DA release from DAT-Cre x ChR2 mice ( Figure S1E ). Collectively, these findings suggest that while the acute inhibition is largely dependent on nAChR activation, the sustained inhibition of DA release is independent of nAChR signaling.
The Sustained Inhibition of DA Release Induced by Oxo-M Is Mediated by M 4 Receptors Expressed on D 1 -SPNs The M 4 receptor is expressed in numerous neuronal populations in the striatum (Figure 2A) . In order to determine the role of M 4 in mediating the sustained inhibition of DA release observed with Oxo-M, we utilized tissue specific knockout mice in combination with the novel M 4 -selective PAM VU0467154. Consistent with its activity as a PAM, application of VU0467154 (3 mM) had no effect on DA release when applied alone ( Figure S1F ), however, VU0467154 significantly potentiated the inhibition of DA release induced by 10 mM Oxo-M at sustained time points (Figures 2B and 2D) , suggesting a key role for M 4 in mediating the sustained inhibition of DA release. However, M 4 is not expressed in DA neurons (Weiner et al., 1990) , suggesting that M 4 is not likely to serve as a presynaptic heteroreceptor that directly inhibits DA release in DA terminals. Since this sustained effect of Oxo-M on DA release is independent of nAChR activation, it is also not likely to be mediated by activation of M 4 autoreceptors on cholinergic terminals. The large majority of M 4 in striatum is present on D 1 -SPNs (Ince et al., 1997) , raising the possibility that this subpopulation of M 4 could in some way modulate DA release. To assess this, we used mice in which M 4 was selectively deleted from D 1 -expressing neurons (D 1 -M 4 knockout [KO] mice). Electrically evoked DA release was similar in magnitude in both D 1 -M 4 KOs and control littermates (floxed M 4 receptor mice; M 4 fl/fl; data not shown). However, the acute inhibition observed upon application of 10 mM Oxo-M was significantly reduced in the D 1 -M 4 KO mice (28.2% ± 9.1% acute inhibition of DA release, n = 6) compared to littermate controls (72.3% ± 7.1% acute inhibition of DA release, n = 6; p < 0.05; and two-tailed Mann-Whitney test), suggesting that M 4 expressed on D 1 neurons may, in part, contribute to the acute inhibition seen with Oxo-M. In the D 1 -M 4 KO mice, the acute inhibition was further enhanced by increasing the Oxo-M concentration to 30 mM ( Figure 2E ), suggesting that M 4 expressed on D 1 -SPNs is not the only subpopulation of mAChRs contributing to this acute response. Importantly, VU0467154 had no effect on Oxo-M modulation of DA release in D 1 -M 4 KO slices at any of the Oxo-M concentrations examined ( Figures 2C-2E ). Furthermore, the sustained inhibition of DA release observed in littermate control mice after application of Oxo-M (30 mM) in the presence of DHbE was completely absent in D 1 -M 4 KO mice (Figures 2F and 2G) . Collectively, these findings suggest that M 4 on D 1 -SPNs contributes to the acute inhibition observed with application of mAChR agonist, but is solely responsible for the sustained inhibition of DA signaling observed after mAChR activation.
M 4 -Mediated Sustained Inhibition of DA Release Requires Intact Diacylglycerol Lipase and CB 2 Cannabinoid Receptor Signaling SPNs do not project to DA terminals, suggesting that in these acute slices M 4 must alter DA release via a form of nonsynaptic transmission. One of the best studied forms of non-synaptic communication in the striatum involves eCB signaling and activation of CB 1 receptors, and this pathway has been demonstrated to play a key role in M 4 -mediated modulation of striatal synaptic plasticity (Shen et al., 2015) . However, the selective CB 1 receptor antagonist AM251 (1 mM) had no effect on M 4 modulation of DA release, suggesting that CB 1 is not involved (data not shown). Interestingly, while the CB 2 cannabinoid receptor is not thought to play a major role in regulation of neurotransmitter release, a recent study suggests that DA neurons express the CB 2 receptor (Zhang et al., 2014) . Thus, we used a combination of genetic and pharmacological tools to determine whether CB 2 receptors play a role in M 4 effects on DA release. Similar to results in M 4 fl/fl mice, VU0467154 significantly potentiated the sustained inhibition of DA release observed after bath application of 10 mM Oxo-M in wild-type (WT) mice (Figures 3A and 3D) . Strikingly, the CB 2 antagonist AM630 (3 mM) had no effect on DA release alone (data not shown), but blocked VU0467154 potentiation of Oxo-M effects ( Figures 3B and 3D) . Furthermore, the effects of VU0467154 were absent in CB 2 KO mice ( Figures 3C and 3D ), confirming a critical role for the CB 2 receptor in mediating this response.
The CB 2 -dependence of the sustained reductions in DA release suggests that activation of M 4 on SPNs could facilitate the formation and/or release of an eCB. Production and concurrent physiological effects of eCBs can be stimulated via a multitude of mechanisms at various synapses with some of these mechanisms being Ca 2+ -dependent and others being Ca 2+ -independent (Gladding et al., 2009 Figure S2 ). In contrast, mAChR activation did not induce Ca 2+ transients in D 1 -SPNs (Figure S2A) . To further evaluate a potential role for intracellular Ca 2+ signaling in the mAChR-induced inhibition of DA release, slices were pretreated with either 3 mM thapsigargin to deplete intracellular Ca 2+ stores or 30 mM 2-aminoethoxydiphenyl borate (2-APB) to antagonize the inositol 1,4,5-trisphosphate (IP 3 ) receptor. None of these treatments had any effect on M 4 -mediated sustained inhibitions of DA release ( Figure 3F ). However, bath application of thapsigargin blocked mGlu-mediated Ca 2+ transients in D 1 -SPNs, suggesting that this treatment was effective at depleting intracellular Ca 2+ stores ( Figures S2C and S2D ).
These data suggest that the observed M 4 -mediated effects on sustained DA release are not likely to be dependent on M 4 -induced Ca 2+ mobilization. Previous examples of Ca 2+ -independent eCB-mediated effects arising from SPNs as well as other brain regions have been demonstrated to occur through diacylglycerol (DAG) lipase, which plays a key role in the synthesis of the eCB 2-arachinonoylglycerol (2-AG; Chevaleyre and Castillo, 2003; Lerner and Kreitzer, 2012) . Interestingly, we found that mAChR-induced sustained reductions in DA release were blocked by pretreatment with the DAG lipase inhibitor DO-34 ( Figures 3E and 3F) . Collectively, these studies suggest that M 4 expressed on SPNs can lead to CB 2 activation through activation of DAG-lipase and formation of the eCB 2-AG.
Efficacy of VU0467154 in Rodent Models of Antipsychotic Efficacy Is Mediated by M 4 in D 1 -Expressing Neurons and Is Blocked by a CB 2 Antagonist We next evaluated the effects of VU0467154 on amphetamineinduced disruption of prepulse inhibition (PPI; Figure 4A ) of the acoustic startle response, a preclinical model of sensory motor gating deficits in schizophrenia patients that is reversed by M 4 PAMs (Byun et al., 2014) . Both D 1 -M 4 KO mice and control littermates (M 4 fl/fl) had similar baseline acoustic startle responses that were not altered by dosing with amphetamine or VU0467154 alone or in combination ( Figure S3 ). VU0467154 (10 mg/kg; intraperitoneal [i.p.]) alone had no effect on PPI compared to vehicle (74.2% ± 3.7% and 72.1% ± 3.8% PPI, respectively). Amphetamine (4 mg/kg; subcutaneous [s.c.]) showing that the effects of VU0467154 (VU'154) on DA release are blocked by pretreatment with the CB 2 antagonist AM630 (3 mM) and absent in CB 2 KO mice (n = 5-6; *significant difference from 10 mM Oxo-M; p < 0.05; and one-way ANOVA with a post hoc Bonferroni test; sustained inhibition of dopamine release depicted at 30 min).
(E and F) Time course (E) and boxplot summaries (F) showing that VU'154-mediated effects on sustained DA release are blocked by pretreating with DAG-Lipase inhibitor DO34 (1 mM), but unaffected by treatment with 2-APB or thapsigargin (n = 5-6; *significant difference from VU'154 + Oxo-M; p < 0.05; and one-way ANOVA with a post hoc Dunnett's test; sustained inhibition of dopamine release depicted at 40 min). All time course data are depicted as the mean ± SEM.
induced a robust decrease in PPI in both control and D 1 -M 4 KO mice ( Figure 4B ). In control littermates, this amphetamine disruption was significantly reversed by pretreatment with VU0467154 ( Figure 4B , left). However, VU0467154 had no effect on amphetamine-disrupted PPI in D 1 -M 4 KO mice ( Figure 4B , right), highlighting the importance of this M 4 subpopulation in mediating VU0467154 effects on antipsychotic-like behaviors. In addition, the CB 2 receptor antagonist AM630 (10 mg/kg; i.p.) inhibited the ability of VU0467154 (10 mg/kg; i.p.) to reverse amphetamine-induced disruption of PPI ( Figure 4C ), but had no effect in the absence of VU0467154 (27.6% ± 7% and 26.3% ± 4.9% PPI in the absence and presence of AM630). We also examined MK801-induced hyperlocomotion, another behavioral paradigm that is used to predict antipsychotic-like efficacy of novel compounds. Consistent with our recent report , VU0467154 significantly reversed MK-801-induced ambulation. This effect of VU0467154 was partially blocked by AM630 ( Figure S4 ). Taken together, these findings support the novel concept that activation of M 4 in D 1 -SPNs induces eCB release, resulting in a CB 2 -mediated sustained inhibition of DA release and that these actions contribute to the antipsychoticlike effects of the M 4 PAM ( Figure 4D ).
DISCUSSION
Clinical findings suggest that modulation of mAChR signaling can be efficacious in the cognitive, negative, and psychotic symptoms in schizophrenic and Alzheimer's disease patients (Bodick et al., 1997; Shekhar et al., 2008) . Preclinical studies suggest that selective activation of the M 4 receptor may provide a strategy to obtain therapeutic effects, while minimizing the side effects observed with broad spectrum cholinergic/muscarinic compounds (Foster et al., 2014a) . However, the mechanism by which M 4 activation exerts antipsychotic efficacy has not been established. Here, we make two key findings that further elucidate the mechanism whereby M 4 activation leads to antipsychotic-like effects in preclinical models. First, we report that activation of M 4 in the striatum causes a sustained reduction in striatal DA release. This M 4 -mediated reduction in DA release is novel in that it is sustained at time points well after washout of mAChR agonists, which is reminiscent of long-term depression (LTD) observed at glutamatergic synapses (Gladding et al., 2009) . Furthermore, the inhibition of DA release is mediated by M 4 receptors expressed on D 1 -SPNs, which are striatal projection neurons that are postsynaptic targets of dopaminergic projections to the striatum. Interestingly, M 4 -mediated sustained reductions in DA release are blocked by inhibiting DAG lipase, suggesting that M 4 on SPNs modulates DA terminals via the eCB signaling molecule 2-AG. Second, we demonstrate that both the VU0467154-mediated effects on DA release and the antipsychotic-like behavioral effects require CB 2 receptor signaling. Collectively, these studies highlight a novel interaction between muscarinic and eCB signaling pathways in the striatum leading to reduced dopaminergic signaling and highlight the importance of these pathways in mediating the antipsychotic-like behavioral effects observed with M 4 PAMs.
Previous studies have suggested that mAChR agonistinduced inhibition of striatal DA release is mediated primarily by autoreceptors on cholinergic interneurons (Threlfell et al., 2010; Zhang et al., 2002) , which may include both M 2 and M 4 mAChR subtypes. Here, we find that Oxo-M induced an acute inhibition of DA release that was significantly reduced either in the presence of nAChR antagonist or with direct optical stimulation of DA terminals. While the acute inhibition was largely nAChRdependent, and accordingly likely to be mediated by autoreceptors, it was not completely abolished under conditions that removed nAChR signaling. Furthermore, the acute inhibition seen with Oxo-M was reduced in D 1 -M 4 KO mice compared to littermate controls. These findings suggest that the acute inhibition observed after mAChR agonist application involves multiple receptor subtypes and populations likely including: M 2 , M 4 (located both presynaptically and postsynaptically), and M 5 (Foster et al., 2014b , Shin et al., 2015 . Importantly, we also report a novel sustained inhibition of DA release that was observed at time points well after removal of Oxo-M. Unlike the acute inhibition, this sustained inhibition of DA release is independent of nAChR-signaling. Application of the M 4 -selective PAM VU0467154 in acute brain slices had no effect on its own, likely owing to the reduced activity of striatal cholinergic interneurons, and corresponding low levels of ACh tone, in ex vivo brain slices compared to in vivo (Shen et al., 2015) . However, when VU0467154 was included with a submaximal concentration of agonist, it potentiated the sustained inhibition of DA release. In the striatum, the majority of M 4 is expressed on D 1 -expressing SPNs, and it was found that the VU0467154-mediated effects on DA release and reversal of specific behavioral effects of psychomotor stimulants were dependent on expression of M 4 expressed in D 1 -SPNs. These data are consistent with a previous report suggesting that some behavioral effects of the nonselective orthosteric mAChR agonist xanomeline also require activation of M 4 receptors on D 1 -expressing neurons (Dencker et al., 2011) . While these data suggest that M 4 on D 1 -SPNs are critically important for mediating antipyschotic-like efficacy, we cannot rule out a role for M 4 expressed on other D 1 -expressing populations. Collectively, these data provide exciting new insights into the mechanisms by which activation of M 4 receptors in these neurons can regulate DA-dependent behaviors.
Because SPNs do not make synaptic connections with DA terminals, we hypothesized that M 4 receptors on SPNs must alter DA release via a form of non-synaptic transmission. A recent study demonstrated that M 4 activation with M 4 PAMs could modulate multiple forms of spike-timing dependent plasticity at corticostriatal synapses via an eCB-dependent mechanism. These effects on plasticity were absent when M 4 was deleted from D 1 -expressing neurons and required intact CB 1 receptor signaling (Shen et al., 2015) . Most previously described eCB actions in the CNS are primarily mediated by CB 1 . However, we found that a selective antagonist of CB 1 receptors did not inhibit the effect of M 4 activation on DA release. In contrast, selective blockade or genetic deletion of CB 2 receptors completely blocked the ability of M 4 PAMs to inhibit DA release. Furthermore, the M 4 -mediated sustained reductions in DA release were completely blocked by a DAG-lipase inhibitor, suggesting a key role for 2-AG in mediating these effects. Collectively, these findings suggest that the subpopulation of M 4 on direct pathway SPNs can efficiently promote eCB signaling in the striatum with important physiological implications. In addition to changes in synaptic plasticity induced by CB 1 activation, reduced DA release via CB 2 activation could impact forms of synaptic plasticity that are modulated by D 1 and D 2 receptor activation. In the future, it will be important to fully parse out the effects of M 4 activation on overall striatal function that are mediated by M 4 on SPNs (regulation of DA release through CB 2 activation, activation of CB 1 receptors on glutamatergic, and GABAergic terminals) and activation of M 4 in other neuronal populations.
The finding that CB 2 was required for M 4 -mediated modulation of DA release was surprising in the light of previous studies indicating that CB 1 and CB 2 were thought to be primarily expressed in the CNS and immune system, respectively. However, this original dichotomy has been challenged by recent studies that have found CB 2 expressed in numerous brain areas (Mechoulam and Parker, 2013) , including data suggesting that DA neurons express CB 2 receptors (Zhang et al., 2014) . Furthermore, CB 2 activation has been demonstrated to modulate cocaine-induced locomotion (Xi et al., 2011) , and CB 2 function has been linked to schizophrenia in patients and to schizophrenia-related behaviors in rodent models (Ishiguro et al., 2010; Ortega-Alvaro et al., 2011) . Furthermore, we demonstrate that CB 2 blockade occluded M 4 -mediated behavioral effects in two preclinical behavioral models predictive of antipsychotic efficacy. While activation of M 4 leading to CB 2 activation on DA terminals is the most parsimonious explanation of our results, it is not clear what population(s) of CB 2 mediate these effects. Further studies with tissue-specific CB 2 KO mice will be needed to determine the role of CB 2 receptors expressed on various neuronal and glial populations in modulating DA release and DA-dependent behaviors. In addition to providing a novel mechanism whereby M 4 activation can lead to antipsychotic-like efficacy, these studies suggest that CB 2 -selective agonists could provide an exciting new therapeutic strategy for the treatment of schizophrenia.
The present study is especially important in the context of currently available antipsychotic agents that act by blocking striatal DA receptors. While exerting antipsychotic activity through blockade of midbrain DA receptors, DA receptor antagonists also block DA receptors in the cortex and other brain regions where they induce adverse effects, including impaired cognitive function. In contrast, M 4 PAMs improve cognitive function in animal models . These studies provide a mechanism by which M 4 may act locally to reduce DA signaling without blockade of DA receptors throughout the CNS. The combined cellular and behavioral studies reported suggest that this mechanism may be responsible, at least in part, for the antipsychotic-like effects of M 4 PAMs.
EXPERIMENTAL PROCEDURES
Voltammetry data plotted with box and whisker plots were analyzed using oneway ANOVA with a Dunnett's or Bonferroni post hoc test where appropriate. Time courses of DA release are depicted as the mean ± SEM. PPI data are expressed as mean ± SEM and analyzed using one-way ANOVA with a Dunnett's post hoc test comparing all dosing groups to amphetamine-treated controls. Experimental procedures are described in detail in the Supplemental Information. All animals were handled in accordance with federal guidelines and protocols approved by Vanderbilt University.
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